Published in Lancet Oncol on November 17, 2010
Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE) | NCT01745289
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927. J Clin Oncol (2015) 2.69
Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat (2014) 2.18
Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst (2013) 1.51
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer (2013) 1.36
Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol (2011) 1.23
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol (2013) 1.13
Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas (2011) 1.11
Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07
Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int (2012) 1.05
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer (2012) 1.04
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause (2013) 1.00
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer (2013) 1.00
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol (2014) 0.98
Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies. Int J Surg Oncol (2015) 0.96
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat (2012) 0.95
p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci (2013) 0.95
Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinol (2014) 0.94
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med (2011) 0.94
Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis (2013) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst (2016) 0.92
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One (2013) 0.92
Tracking progesterone receptor-mediated actions in breast cancer. Pharmacol Ther (2013) 0.91
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol (2011) 0.91
Increased fracture rate in women with breast cancer: a review of the hidden risk. BMC Cancer (2011) 0.91
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer (2014) 0.90
Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial? Breast Care (Basel) (2014) 0.90
Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis. Onco Targets Ther (2015) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. Front Oncol (2012) 0.89
The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. Int J Breast Cancer (2011) 0.88
Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat (2013) 0.86
HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med (2014) 0.86
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat (2012) 0.86
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis (2012) 0.86
Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends. Br J Cancer (2014) 0.85
Exemestane for breast cancer prevention: a critical shift? Cancer Discov (2012) 0.85
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol (2012) 0.85
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer (2012) 0.84
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. Br J Cancer (2011) 0.84
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1. Nat Commun (2014) 0.83
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat (2014) 0.83
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol (2015) 0.83
Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia (2014) 0.83
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med (2013) 0.83
Multicriteria decision analysis in oncology. Health Expect (2014) 0.83
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer. Curr Breast Cancer Rep (2014) 0.83
Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases. Breast Cancer Res Treat (2014) 0.83
Breast cancer survivorship issues. Hematol Oncol Clin North Am (2013) 0.82
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd (2015) 0.82
The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. Cancer Causes Control (2012) 0.82
Mammographic breast density response to aromatase inhibition. Clin Cancer Res (2013) 0.82
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer. PLoS One (2014) 0.82
Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst (2014) 0.82
Highlights from the ninth European breast cancer conference, glasgow, 19-21 march 2014. Ecancermedicalscience (2014) 0.82
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel) (2015) 0.82
Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. Oncotarget (2016) 0.82
The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. J Adv Pract Oncol (2014) 0.82
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast Care (Basel) (2013) 0.81
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat (2015) 0.81
Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada. Curr Oncol (2015) 0.81
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study. Support Care Cancer (2012) 0.81
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer. J Breast Cancer (2015) 0.80
Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature. Rep Pract Oncol Radiother (2013) 0.80
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget (2015) 0.80
Fracture in asian women with breast cancer occurs at younger age. PLoS One (2013) 0.80
Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer (2015) 0.80
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer. Cancer Sci (2014) 0.80
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol (2015) 0.80
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. Br J Cancer (2015) 0.79
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs. Onco Targets Ther (2014) 0.78
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer. Ann R Coll Surg Engl (2013) 0.78
Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy. Breast Cancer (Dove Med Press) (2014) 0.78
Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players. Front Oncol (2016) 0.78
The Manchester guidelines for contralateral risk-reducing mastectomy. World J Surg Oncol (2015) 0.78
Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep (2012) 0.78
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer (Dove Med Press) (2011) 0.78
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Res Treat (2016) 0.78
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells. BMC Cancer (2016) 0.77
Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. Cancer Prev Res (Phila) (2016) 0.77
Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). PLoS One (2012) 0.77
The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model. Reprod Biol Endocrinol (2014) 0.77
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study. Cancer Manag Res (2012) 0.77
Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells. J Steroid Biochem Mol Biol (2015) 0.77
Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. J Comp Eff Res (2013) 0.77
Induction of Integrin Signaling by Steroid Sulfatase in Human Cervical Cancer Cells. Biomol Ther (Seoul) (2016) 0.77
Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncol (2016) 0.76
Genomic Disparities in Breast Cancer Among Latinas. Cancer Control (2016) 0.76
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene (2016) 0.76
Cancer Treatment-Induced Bone Loss in women with breast cancer. Bonekey Rep (2015) 0.76
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med (2005) 12.99
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol (2007) 7.45
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Aromatase inhibitors in breast cancer. N Engl J Med (2003) 5.01
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol (2005) 4.74
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Women need better information about routine mammography. BMJ (2003) 3.77
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol (2011) 3.73
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst (2011) 3.73
Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation (2007) 3.71
Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst (2006) 3.65
Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst (2004) 3.53
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol (2008) 3.23
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol (2005) 3.19
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol (2012) 3.16
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 3.00
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Mechanisms of tamoxifen resistance. Endocr Relat Cancer (2004) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Intraoperative radiotherapy for breast cancer. Lancet Oncol (2004) 2.91
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol (2002) 2.87
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72
Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle (2011) 2.68
Tissue screening after breast reduction. BMJ (2009) 2.67
Call for doctors not to practice homeopathy or refer to homeopaths. N Z Med J (2011) 2.66
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol (2010) 2.63
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol (2005) 2.58
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle (2011) 2.39
Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer (2010) 2.35
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab (2011) 2.32
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle (2010) 2.32
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol (2013) 2.28
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle (2010) 2.26
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol (2011) 2.26
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer (2011) 2.15
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol (2005) 2.12
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle (2010) 2.10
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol (2007) 2.09
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal (2011) 2.04
Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol (2011) 2.03
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01